Impact of visceral adiposity on glycemic variability in patients with insulin-treated type 2 diabetes undergoing hemodialysis

Table 1 Glucometrics data of type 2 diabetes with end-stage kidney disease between hemodialysis days and off-hemodialysis for 20 days, mean ± SD

Glucometrics by continuous glucose monitoring	HD	Off-HD	P value
Mean continuous glucose monitoring (mg/dL)	172.15 ± 41.53	182.49 ± 48.92	0.004
SD (mg/dL)	52.93 ± 16.24	49.37 ± 15.59	0.004
Time in range (%)	62.68 ± 19.93	57.06 ± 23.05	0.008
TAR1 (> 180 mg/dL) (%)	22.72 ± 9.15	26.63 ± 10.61	0.017
TAR2 (> 250 mg/dL) (%)	13.41 ± 14.04	14.64 ± 17.97	0.17
TBR1 (< 70 mg/dL) (%)	1.65 ± 2.91	0.95 ± 1.27	0.25
TBR2 (< 54 mg/dL) (%)	0.75 ± 2.71	0.31 ± 0.70	0.60
Glucose management indicator vs glycated hemoglobin (%)	7.31 ± 0.78 vs 6.98 ± 1.38		0.001

HD: Hemodialysis; Off-HD: Non-hemodialysis days; SD: Standard deviation; TAR: Time above range; TBR: Time below range.